Takeda Japan Implements AI-Driven Demand Forecasting to Strengthen Domestic Pharmaceutical Supply Chain

2025年8月4日

Takeda becomes one of the first pharmaceutical companies in Japan to implement an AI-powered demand forecasting model
In addition to enhancing supply reliability, the initiative is expected to reduce pharmaceutical waste and improve cash flow—contributing to both environmental and financial sustainability

Osaka, Japan, August 4, 2025 – Takeda (TSE: 4502/NYSE: TAK) today announced that its Japan Manufacturing and Supply organization has implemented a new AI-based demand forecasting model to optimize pharmaceutical production planning.

Traditionally, demand forecasting in Japan has relied on historical data and expert insights. With the adoption of artificial intelligence, Takeda Japan can now identify nonlinear trends and complex patterns across large datasets—enabling more precise and comprehensive forecasting. By integrating AI-generated insights with human expertise, the company has developed a more agile and responsive forecasting system, capable of more frequent updates, reflection in production planning and faster adaptation to market changes.

Initially, the AI model will be applied to mature products with high shipping frequency and sufficient historical data to support machine learning. As more data is accumulated, Takeda Japan plans to expand the use of AI forecasting to a broader range of products.

Optimizing inventory with these high-accuracy forecasts will not only enhance supply reliability across Japan but also help reduce the disposal of expired inventory and improve cash flow—delivering both environmental and economic benefits. This initiative is part of Takeda’s global transformation to drive digitalization of our supply chain.

Tomohiro Yoshinari, Head of Japan Supply Chain, Global Manufacturing & Supply at Takeda, said, “We remain committed to advancing the accuracy of our demand forecasting and driving sustainable operational efficiency. Our mission is to ensure that patients in Japan receive the medicines they need, when they need them—and we will continue to innovate to fulfill that promise.”

* Takeda becomes one of the first pharmaceutical companies in Japan to implement an AI-powered demand forecasting model * In addition to enhancing supply reliability, the initiative is expected to reduce pharmaceutical waste and improve cash flow—contributing to both environmental and financial sustainability **Osaka, Japan, August 4, 2025** – Takeda ([TSE: 4502/NYSE: TAK](/investors/overview/)) today announced that its Japan Manufacturing and Supply organization has implemented a new AI-based demand forecasting model to optimize pharmaceutical production planning. Traditionally, demand forecasting in Japan has relied on historical data and expert insights. With the adoption of artificial intelligence, Takeda Japan can now identify nonlinear trends and complex patterns across large datasets—enabling more precise and comprehensive forecasting. By integrating AI-generated insights with human expertise, the company has developed a more agile and responsive forecasting system, capable of more frequent updates, reflection in production planning and faster adaptation to market changes. Initially, the AI model will be applied to mature products with high shipping frequency and sufficient historical data to support machine learning. As more data is accumulated, Takeda Japan plans to expand the use of AI forecasting to a broader range of products. Optimizing inventory with these high-accuracy forecasts will not only enhance supply reliability across Japan but also help reduce the disposal of expired inventory and improve cash flow—delivering both environmental and economic benefits. This initiative is part of Takeda’s global transformation to drive digitalization of our supply chain. Tomohiro Yoshinari, Head of Japan Supply Chain, Global Manufacturing & Supply at Takeda, said, “We remain committed to advancing the accuracy of our demand forecasting and driving sustainable operational efficiency. Our mission is to ensure that patients in Japan receive the medicines they need, when they need them—and we will continue to innovate to fulfill that promise.”

About Takeda

Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com.

Contact: Kumi Iiyama kumi.iiyama@takeda.com 080-5789-7742

Forward-Looking Statements

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could”, “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings-and-security-reports/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results, except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom.
This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could”, “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: [https://www.takeda.com/investors/sec-filings-and-security-reports/](/investors/sec-filings-and-security-reports/) or at [www.sec.gov](http://www.sec.gov). Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results, except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

Takeda Japan Implements AI-Driven Demand Forecasting to Strengthen Domestic Pharmaceutical Supply Chain | Takeda Pharmaceuticals